Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
SUPPLEMENTARY MATERIALS AND METHODS

Study cohort
The retrospective set of 1,850 tumor tissues from radical prostatectomy (RP) expression profiles with clinical follow up and outcomes data were pooled from five institutions (Mayo Clinic I & 2: n=777, Thomas Jefferson: n=133, Cleveland Clinic: n=182, John Hopkins: n=638, Durham VA: n=120) that were from previously reported studies [Supplementary Table 1] . Most of these patients have clinical variables and metastatic outcome follow-up up to 13 years. The prospective set of 8,532 tumor tissues from RP and 1,694 from biopsy expression profiles from de-identified and anonymized Decipher Prostate Cancer Classifier were retrieved from the GRID. These profiles had associated pathological variables, but no outcomes data.
Total RNA was extracted and purified using the RNeasy FFPE kit (Qiagen, Valencia, CA). RNA was amplified and labeled using the Ovation FFPE WTA system (NuGen, San Carlos, CA) and hybridized to Human Exon 1.0 ST GeneChips (Affymetrix, Santa Clara, CA). Quality control was performed using Affymetrix Power Tools [15] , and normalization was performed using the Single Channel Array Normalization (SCAN) algorithm [16] .
Enrichment analysis
Genes were ranked based on their Pearson's correlation to PCA3 in the prospective cohort and gene set enrichment analysis (GSEA) was carried out to identify gene sets associated with PCA3 by using the GSEA analysis tool (version 2.2.0) downloaded from the Broad Institute website (http://www.broadinstitute.org/ gsea). The curated gene sets of the Molecular Signature Database (MSigDB) version 4.0 was used for enrichment. The false discovery rate (FDR) for GSEA is the estimated probability that a gene set with a given normalized enrichment score (NES) represents a false-positive finding, and an FDR <0.25 is considered to be statistically significant for GSEA. 
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